
## **Chantal Housset**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/702846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101784.	0.7	2
2	A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101801.	0.7	8
3	Editorial: Clinical and pathogenic novelties in cholangiopathies: new treatments and many more to come. Current Opinion in Gastroenterology, 2022, 38, 81-82.	1.0	0
4	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. Hepatology, 2022, 76, 1360-1375.	3.6	30
5	Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. JHEP Reports, 2021, 3, 100201.	2.6	24
6	Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
7	Role of Angiogenesis in the Pathogenesis of NAFLD. Journal of Clinical Medicine, 2021, 10, 1338.	1.0	19
8	Effect of CFTR correctors on the traffic and the function of intracellularly retained ABCB4 variants. Liver International, 2021, 41, 1344-1357.	1.9	4
9	Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166067.	1.8	9
10	RAB10 Interacts with ABCB4 and Regulates Its Intracellular Traffic. International Journal of Molecular Sciences, 2021, 22, 7087.	1.8	3
11	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Reports, 2021, 3, 100298.	2.6	6
12	Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. Journal of Experimental Medicine, 2021, 218, .	4.2	20
13	Editorial: Immunity from trigger to therapy in hepatobiliary diseases. Current Opinion in Gastroenterology, 2021, 37, 77-78.	1.0	0
14	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut, 2020, 69, 92-102.	6.1	136
15	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	0.8	8
16	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 72, 627-635.	1.8	84
17	Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	18
18	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	1.1	10

CHANTAL HOUSSET

#	Article	IF	CITATIONS
19	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2785-2792.e3.	2.4	43
20	Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models. Scientific Reports, 2019, 9, 6653.	1.6	12
21	Editorial: simplifying screening for primary liver cancer - do the LCR1 and LCR2 tests hold the key? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 613-614.	1.9	Ο
22	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 1878-1885.	0.2	24
23	LCR1 and LCR2, two multiâ€enalyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 308-320.	1.9	15
24	Dietâ€Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. Hepatology Communications, 2018, 2, 1533-1549.	2.0	28
25	Endoplasmic reticulum stress induces inverse regulations of major functions in portal myofibroblasts during liver fibrosis progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3688-3696.	1.8	13
26	Longâ€ŧerm prognostic value of the FibroTest in patients with nonâ€alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1117-1127.	1.9	28
27	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 521-528.	0.7	40
28	Targeted pharmacotherapies for defective ABC transporters. Biochemical Pharmacology, 2017, 136, 1-11.	2.0	31
29	Expression patterns of nuclear receptors in parenchymal and non-parenchymal mouse liver cells and their modulation in cholestasis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1699-1708.	1.8	18
30	Functional defect of variants in the adenosine triphosphate–binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VXâ€770). Hepatology, 2017, 65, 560-570.	3.6	40
31	A PDZ-Like Motif in the Biliary Transporter ABCB4 Interacts with the Scaffold Protein EBP50 and Regulates ABCB4 Cell Surface Expression. PLoS ONE, 2016, 11, e0146962.	1.1	9
32	Culture Model of Rat Portal Myofibroblasts. Frontiers in Physiology, 2016, 7, 120.	1.3	11
33	A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3. Hepatology, 2016, 63, 1620-1631.	3.6	81
34	Functions of the Gallbladder. , 2016, 6, 1549-1577.		99
35	Portal myofibroblasts connect angiogenesis and fibrosis in liver. Cell and Tissue Research, 2016, 365, 583-589.	1.5	32
36	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open, 2015, 5, e010017.	0.8	9

CHANTAL HOUSSET

#	Article	IF	CITATIONS
37	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology, 2015, 61, 1041-1055.	3.6	102
38	Phosphorylation of ABCB4 impacts its function: Insights from disease-causing mutations. Hepatology, 2014, 60, 610-621.	3.6	43
39	ABCB4: Insights from pathobiology into therapy. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 557-563.	0.7	22
40	Characterization of animal models for primary sclerosing cholangitis (PSC). Journal of Hepatology, 2014, 60, 1290-1303.	1.8	129
41	Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: A study of 156 consecutive patients. Hepatology, 2013, 58, 1105-1110.	3.6	105
42	Effects of Cellular, Chemical, and Pharmacological Chaperones on the Rescue of a Trafficking-defective Mutant of the ATP-binding Cassette Transporter Proteins ABCB1/ABCB4. Journal of Biological Chemistry, 2012, 287, 5070-5078.	1.6	47
43	Distinct proteomic features of two fibrogenic liver cell populations: Hepatic stellate cells and portal myofibroblasts. Proteomics, 2010, 10, 1017-1028.	1.3	56